The US Food and Drug Administration (FDA) has approved a new indication for Breyanzi (lisocabtagene maraleucel) as the first chimeric antigen receptor (CAR)-T therapy in the US for treatment of adults with marginal zone lymphoma (MZL) who have failed treatment with or relapsed after two or more prior lines of therapy.   “Today’s approval represents a […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!